Form 4: Supernus Pharmaceuticals SVP, Chief Medical Officer Jonathan Rubin Reports Changes in Beneficial Ownership

Jonathan Rubin, SVP and Chief Medical Officer of Supernus Pharmaceuticals, reports acquisition and disposal of common stock and restricted stock units.

Summary

• On February 23, 2024, Jonathan Rubin, SVP, Chief Medical Officer of Supernus Pharmaceuticals, acquired 1,250 shares of common stock.
• On the same day, Rubin disposed of 567 shares of common stock to satisfy tax withholding requirements related to RSU vesting at a price of $29.06.
• Following these transactions, Rubin directly owns 4,641 shares of common stock.
• Rubin also disposed of 1,250 Restricted Stock Units (RSUs) which vest in four equal annual installments beginning February 23, 2024, leaving him with 3,750 RSUs.

Sentiment

Score: 5

Explanation: Neutral sentiment as the filing reflects routine transactions related to executive compensation and tax obligations.

Positives

• The acquisition of 1,250 shares could be interpreted as a positive sign of confidence in the company's future.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they primarily reflect internal compensation adjustments.

Key Dates